Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

Journal of Clinical Oncology

Volumn 27, Issue 23, 2009, Pages 3742-3748

  Attard, Gerhardt ^a   Reid, Alison H M ^a   A'Hern, Roger ^a   Parker, Christopher ^a   Oommen, Nikhil Babu ^a   Folkerd, Elizabeth ^a   Messiou, Christina ^a   Molife, L Rhoda ^a   Maier, Gal ^a   Thompson, Emilda ^a   Olmos, David ^a   Sinha, Rajesh ^a   Lee, Gloria ^a   Dowsett, Mitch ^a   Kaye, Stan B ^a   Dearnaley, David ^a   Kheoh, Thian ^a   Molina, Arturo ^a   De Bono, Johann S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN; BICALUTAMIDE; CORTICOTROPIN; CYTOCHROME P450 17; DEXAMETHASONE; DIETHYLSTILBESTROL; DOCETAXEL; EPLERENONE; ESTRADIOL; GLUCOCORTICOID; GONADORELIN DERIVATIVE; KETOCONAZOLE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ROMIDEPSIN; VENLAFAXINE; ABIRATERONE; ANDROSTANE DERIVATIVE; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CORTICOSTEROID; ENZYME INHIBITOR; STEROID 17ALPHA MONOOXYGENASE; TESTOSTERONE;

ADD ON THERAPY; ADULT; AGED; ALTERNATIVE HYPOTHESIS; AMINOTRANSFERASE BLOOD LEVEL; ANDROGEN BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASTHMA; CANCER CHEMOTHERAPY; CASTRATION; CELL COUNT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG DOSE ESCALATION; ENZYME INHIBITION; ESTRADIOL BLOOD LEVEL; FLUID OVERLOAD; HEADACHE; HOT FLUSH; HUMAN; HUMAN CELL; HYPERTENSION; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NULL HYPOTHESIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHYSICAL DISEASE BY COMPOSITION OF BODY FLUIDS, EXCRETA AND SECRETIONS; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; PROSTATE CANCER; RECOMMENDED DRUG DOSE; SIDE EFFECT; TUMOR CELL; BLOOD; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG RESISTANCE; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; NEOPLASM; PATHOLOGY; PROSTATE TUMOR;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROSTENOLS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE; TESTOSTERONE;

EID: 68949094223     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.0642     Document Type: Article

References (38)

1. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 355:1491-1498, 2000
2. Hellerstedt BA, Pienta KJ: The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52:154-179, 2002
3. Attard G, Belldegrun AS, de Bono JS: Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 96: 1241-1246, 2005
4. Labrie F, Dupont A, Belanger A, et al: New hormonal therapy in prostatic carcinoma: Combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5:267-275, 1982
5. Mohler JL, Gregory CW, Ford OH 3rd, et al: The androgen axis in recurrent prostate cancer. Clin Cancer Res 10:440-448, 2004
6. Montgomery RB, Mostaghel EA, Vessella R, et al: Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 68: 4447-4454, 2008
7. Locke JA, Guns ES, Lubik AA, et al: Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68:6407-6415, 2008
8. Small EJ, Halabi S, Dawson NA, et al: Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). J Clin Oncol 22:1025-1033, 2004
9. Barrie SE, Rowlands MG, Foster AB, et al: Inhibition of 17 alpha-hydroxylase/C17-C20 lyase by bifluranol and its analogues. J Steroid Biochem 33:1191-1195, 1989
10. Jarman M, Barrie SE, Deadman JJ, et al: Hydroxyperfluoroazobenzenes: Novel inhibitors of enzymes of androgen biosynthesis. J Med Chem 33:2452-2455, 1990
11. Jarman M, Barrie SE, Leung CS, et al: Selective inhibition of cholesterol side-chain cleavage by potential pro-drug forms of aminoglutethimide. Anticancer Drug Des 3:185-190, 1988
12. McCague R, Rowlands MG, Barrie SE, et al: Inhibition of enzymes of estrogen and androgen biosynthesis by esters of 4-pyridylacetic acid. J Med Chem 33:3050-3055, 1990
13. Potter GA, Barrie SE, Jarman M, et al: Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): Potential agents for the treatment of prostatic cancer. J Med Chem 38:2463-2471, 1995
14. Barrie SE, Potter GA, Goddard PM, et al: Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/ C17-20 lyase). J Steroid Biochem Mol Biol 50:267-273, 1994
15. Attard G, Reid A, Yap T, et al: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer (CRPC) commonly remains hormone driven. J Clin Oncol 26:4563-4571, 2008
16. O'Donnell A, Judson I, Dowsett M, et al: Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90:2317-2325, 2004
17. Grigoryev DN, Long BJ, Njar VC, et al: Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor. J Steroid Biochem Mol Biol 75:1-10, 2000
18. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461-3467, 1999
19. Luthy IA, Begin DJ, Labrie F: Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem 31:845-852, 1988
20. Allard WJ, Matera J, Miller MC, et al: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897-6904, 2004
21. Tibbe AG, de Grooth BG, Greve J, et al: Imaging technique implemented in CellTracks system. Cytometry 47:248-255, 2002
22. Petrylak DP, Ankerst DP, Jiang CS, et al: Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98:516-521, 2006
23. Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159, 2008
24. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
25. Danila DC, Heller G, Gignac GA, et al: Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13:7053-7058, 2007
26. Olmos D, Arkenau HT, Ang JE, et al: Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): A single-centre experience. Ann Oncol 20:27-33, 2009
27. De Bono JS, Scher H, Montgomery RB, et al: Circulating tumor cells predict survival benefit from treatment in metastatic castration resistant prostate cancer. Clin Cancer Res 14:6302-6309, 2008
28. Taplin ME, Rajeshkumar B, Halabi S, et al: Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21:2673-2678, 2003
29. Venkitaraman R, Thomas K, Huddart RA, et al: Efficacy of low-dose dexamethasone in castrationrefractory prostate cancer. BJU Int 101:440-443, 2008
30. Green SJ, Dahlberg S: Planned versus attained design in phase II clinical trials. Stat Med 11:853-862, 1992
31. Figg WD, Liu Y, Arlen P, et al: A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol 173:790-796, 2005
32. Small EJ, Baron AD, Fippin L, et al: Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 157:1204-1207, 1997
33. Millikan R, Baez L, Banerjee T, et al: Randomized phase 2 trial of ketoconazole and ketoconazole/ doxorubicin in androgen independent prostate cancer. Urol Oncol 6:111-115, 2001
34. Wilkinson S, Chodak G: An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer. Eur Urol 45:581-584, 2004
35. Harris KA, Weinberg V, Bok RA, et al: Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 168:542-545, 2002
36. Small EJ, Meyer M, Marshall ME, et al: Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 18:1440-1450, 2000
37. de Bono JS, Bellmunt J, Attard G, et al: Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormonerefractory prostate cancer. J Clin Oncol 25:257-262, 2007
38. Ryan CJ, Halabi S, Ou SS, et al: Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: Results from a Cancer and Leukemia Group B study. Clin Cancer Res 13:2030-2037, 2007